Source-grounded facts extracted from OSR Holdings, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
OSR Holdings, Inc.: Changed corporate name from OSR Holdings, Inc. to OSR Health, Inc. by filing Certificate of Revival of Charter (effective 2026-06-11).
“Effective June 11, 2026, OSR Health, Inc. (formerly OSR Holdings, Inc.) (the “Company”) changed its corporate name from “OSR Holdings, Inc.” to “OSR Health, Inc.””
OSR Holdings, Inc. entered into Asset Purchase Agreement with Vaximm AG valued at $30,000,000 (effective 2026-05-27).
“On May 27, 2026, OSR Holdings, Inc. (the “Company”) entered into an Asset Purchase Agreement (the “Asset Purchase Agreement”) with Vaximm AG (“Vaximm”), a clinical-stage biopharmaceutical company organized under the laws of Switzerland.”
OSR Holdings, Inc. entered into License Agreement with BCM Europe AG valued at up to $815,000,000 (effective 2026-04-29).
“Global Exclusive License Agreement On April 29, 2026, OSR Holdings, Inc. (the “Company”), together with its wholly-owned subsidiary Vaximm AG (“Vaximm”), entered into a Global Exclusive License Agreement (the “License”
OSR Holdings, Inc. issued convertible note to White Lion Capital, LLC, d/b/a White Lion GBM Innovation Fund for $1,055,555.55 principal amount; received $500,000 in cash and reduction of $2,019,290 of amounts outstanding under an existing warrant.
“On April 7, 2026, the Company entered into a Note Purchase Agreement (the “Note Purchase Agreement”) with White Lion, pursuant to which the Company agreed to issue a Senior Secured Convertible Promissory Note in the principal amount of $1,055,555.55 (the “Note”). In consideration for the issuance of the Note, the Company received (i) $500,000 in cash and (ii) a reduction of $2,019,290 of amounts outstanding under an existing warrant held by White Lion, resulting in such warrant having no remaining value and being effectively cancelled.”
OSR Holdings, Inc. incurred convertible notes of $1,055,555.55 with White Lion Capital, LLC at 5% per annum maturing nine-month anniversary of its issuance date.
“On April 7, 2026, the Company issued the Note in the original principal amount of $1,055,555.55, bearing interest at 5% per annum and maturing in nine months.”
OSR Holdings, Inc. entered into Note Purchase Agreement with White Lion Capital, LLC valued at principal amount of $1,055,555.55 Senior Secured Convertible Promissory Note; Company received $500, (effective 2026-04-07).
“Also on April 7, 2026, the Company entered into a Note Purchase Agreement (the “Note Purchase Agreement”) with White Lion, pursuant to which the Company agreed to issue a Senior Secured Convertible Promissory Note in the principal amount of $1,055,555.55 (the “Note”).”
OSR Holdings, Inc. entered into Amendment No. 2 to the Common Stock Purchase Agreement with White Lion Capital, LLC valued at introduces additional purchase mechanisms including intraday purchase notices and fixed purchase not (effective 2026-04-07).
“On April 7, 2026, OSR Holdings, Inc. (the “Company”) entered into Amendment No. 2 to the Common Stock Purchase Agreement (the “ELOC Amendment”) with White Lion Capital, LLC, d/b/a White Lion GBM Innovation Fund (“White Lion”), which amends that certain Common Stock Purchase Agreement, dated February 25, 2025, as previously amended.”
OSR Holdings, Inc. entered into Binding Term Sheet with BCM Europe AG valued at up to $815.0 million in milestone payments (effective 2026-03-27).
“On March 27, 2026, OSR Holdings, Inc. (the “Company” or “OSRH”), together with its wholly-owned subsidiary Vaximm AG (“Vaximm”), entered into a Binding Term Sheet (the “Term Sheet”) with BCM Europe AG (“BCME”) relating to a revised global exclusive license arrangement for VXM01.”
OSR Holdings, Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2)).
“March 5, 2026, OSR Holdings, Inc. (the “Company”) received a written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that Nasdaq has granted the Company an additional 180 calendar day period, or until August 31, 2026, to regain compliance with Nasdaq Listing Rule 5550(a)(2), which requires listed securities to maintain a minimum bid price of $1.00 per share. As previously disclosed, on September 5, 2025, the Company received notice from Nasdaq that the closing bid price of the Company’s common stock had fallen below the required”
OSR Holdings, Inc. completed an acquisition involving Woori IO Co., Ltd. (closed 2026-01-26).
“On January 26, 2026 (the “Closing Date”), OSR Holdings Co., Ltd. (“OSRK”), a subsidiary of OSR Holdings, Inc. (the “Company”), completed the share exchange transaction contemplated by the Share Exchange Agreement dated October 13, 2025”
OSR Holdings, Inc. entered into Binding Term Sheet with BCM Europe AG valued at $30.0 million (comprised of $15.0 million in cash and $15.0 million in digital assets) and up to $81 (effective 2025-01-13).
“On January 13, 2025, Vaximm AG, a wholly-owned subsidiary of OSR Holdings, Inc. (the “Company”), entered into a Binding Term Sheet (the “Term Sheet”) with BCM Europe AG (“BCME”), the largest shareholder of the Company, relating to a proposed global exclusive license of Vaximm’s VXM01 oral cancer immunotherapy platform.”
OSR Holdings, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).
“September 5, 2025, OSR Holdings, Inc. (the “Company”) received a written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company is not in compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2), because the closing bid price of the Company’s common stock has been below $1.00 per share for 30 consecutive business days. The notice has no immediate effect on the listing or trading of the Company’s securities, which will continue to trade on The Nasdaq Capital Market under the symbols “OSRH” and”
Dr. Constance Höfer was appointed as Chief Scientific Officer at OSR Holdings, Inc..
“On March 24, 2025, the Board of Directors of OSR Holdings, Inc. (the “Company”) appointed Dr. Constance Höfer as the Company’s Chief Scientific Officer , effective immediately.”
OSR Holdings, Inc.: As a result of the Business Combination, the Company ceased to be a shell company (effective 2025-02-14).
“As a result of the Business Combination, the Company ceased to be a shell company.”
OSR Holdings, Inc. underwent a change of control involving OSR Holdings Co., Ltd. (closed 2025-02-14).
“OSR Holdings, Inc. (f/k/a Bellevue Life Sciences Acquisition Corp.) (the “ Company ”) completed its previously announced business combination (the “ Business Combination ”) with OSR Holdings Co., Ltd.”
Sang Hoon Kim was appointed as Head of Corporate Venture Capital at OSR Holdings, Inc..
“Sang Hoon Kim is Head of Corporate Venture Capital”
Gihyoun Bang was appointed as Chief Financial Officer at OSR Holdings, Inc..
“Gihyoun Bang is Chief Financial Officer”
Jun Chul Whang was appointed as Chief Legal Officer and Secretary at OSR Holdings, Inc..
“Jun Chul Whang is Chief Legal Officer and Secretary”
Kuk Hyoun Hwang was appointed as President and Chief Executive Officer at OSR Holdings, Inc..
“Kuk Hyoun Hwang is the President and Chief Executive Officer of the Company”
David J. Yoo resigned as Chief Financial Officer at OSR Holdings, Inc..
“David J. Yoo resigned from his position as BLAC's Chief Financial Officer.”
OSR Holdings, Inc.: Approved amendments to the bylaws, including changes to quorum and other governance provisions, to be effective upon completion of the business combination (effective 2025-02-13).
“Proposals No. 3A-3F – The Advisory Governance Proposals Six separate governance proposals (on a non-binding advisory basis in accordance with the requirements of the U.S Securities and Exchange Commission) relating to material differences between the current certificate of incorporation and the Amended Charter, and the current bylaws of BLAC and Amended and Restated Bylaws of BLAC to be in effect upon completion of the Business Combination.”
OSR Holdings, Inc.: Approved and filed an Amended and Restated Certificate of Incorporation, including changes to name, preferred stock authorization, removal of directors voting requirement, corporate opportunity doctrine, quorum requirements, and other SPAC-related provisions (effective 2025-02-13).
“On February 13, 2025, Bellevue Life Sciences Acquisition Corp. (“ BLAC ”) filed an Amended and Restated Certificate of Incorporation with the Secretary of the State of Delaware.”
OSR Holdings, Inc.: Amended charter to remove the net tangible asset requirement (effective 2024-11-12).
“The stockholders also approved a proposal to amend the Charter to remove the net tangible asset requirement in order to expand the methods that the Company may employ so as not to become subject to the “penny stock” rules of the U.S. Securities and Exchange Commission”
OSR Holdings, Inc.: Amended charter to extend business combination deadline from November 14, 2024 to February 14, 2025 (effective 2024-11-12).
“The Certificate of Amendment to the Charter (the “ Charter Amendment ”) was filed with the Delaware Secretary of State and has an effective date of November 12, 2024.”
Sang Hyun Kim was appointed as Director at OSR Holdings, Inc..
“On June 23, 2024, the Board of Directors (the “Board”) of Bellevue Life Sciences Acquisition Corp. (the “Company”) appointed Mr. Sang Hyun Kim as a director, effective immediately.”
Radclyffe Roberts resigned as Member of the Board of Directors at OSR Holdings, Inc..
“On June 7, 2024, Radclyffe Roberts also provided notice of his resignation as member of the Board and as a member of the Board’s Compensation Committee (the “Compensation Committee”) as well as a member and chair of the Board’s M&A Committee.”
Inchul Chung resigned as Member of the Board of Directors at OSR Holdings, Inc..
“On June 7, 2024, Inchul Chung provided notice of his resignation as a member of the Board of Directors (the “Board”) of Bellevue Life Sciences Acquisition Corp. (the “Company”) and as a member of the Board’s Audit Committee (the “Audit Committee”).”
Phil Geon Lee was appointed as Director at OSR Holdings, Inc..
“On May 27, 2024, the BLAC Board appointed Mr. Phil Geon Lee as a director, effective immediately.”
Steven Reed resigned as Director at OSR Holdings, Inc..
“On May 24, 2024, Steven Reed provided notice of his resignation as a member of the BLAC Board of Directors (the “ BLAC Board ”) effective immediately”
OSR Holdings, Inc.: The Company amended its charter to extend the business combination deadline from May 14, 2024 to November 14, 2024 (effective 2024-05-14).
“On May 14, 2024, the Company held a special meeting of its stockholders (the “ Special Meeting ”). At the Special Meeting, the Company’s stockholders approved a proposal (the “ Extension Amendment Proposal ”) to amend to the Company’s Amended and Restated Certificate of Incorporation (the “ Charter ”) to allow the Company to extend the date by which the Company must consummate a business combination from May 14, 2024, to November 14, 2024. The Certificate of Amendment to the Charter (the “ Charter Amendment ”) was filed with the Delaware Secretary of State and has an effective date of May 14, 2024.”
OSR Holdings, Inc. shareholders approved approval of adjournment of the Special Meeting to a later date or dates, if necessary, to permit further solicitation and vote of proxies in the event that there are insufficient votes to approve the Extension Amendment Proposal or to establish quorum at the 2024-05-14 meeting.
“Proposal 2 - Adjournment Proposal The stockholders approved the proposal to approve the adjournment of the Special Meeting to a later date or dates, if necessary, to permit further solicitation and vote of proxies in the event that there are insufficient votes to approve the Extension Amendment Proposal or to establish quorum by the votes set forth in the table below: FOR AGAINST ABSTAIN BROKER NON-VOTES 3,831,081 507,414 — —”
OSR Holdings, Inc. shareholders approved amendment to the Charter to allow the Company to extend the date by which the Company must consummate a business combination from May 14, 2024 to November 14, 2024 at the 2024-05-14 meeting.
“Proposal 1 - Extension Amendment Proposal The stockholders approved the proposal to amend the Charter to allow the Company to extend the date by which the Company must consummate a business combination from May 14, 2024 to November 14, 2024 by the votes set forth in the table below: FOR AGAINST ABSTAIN BROKER NON-VOTES 3,835,399 503,096 — —”
OSR Holdings, Inc. incurred loan of $140,000 with Bellevue Global Life Sciences Investors LLC at not interest bearing maturing the earlier of: (i) December 31, 2024 or (ii) the date on which the Company consummates an initial business combination.
“On May 14, 2024, Bellevue Life Sciences Acquisition Corp. (the " Company ") issued an unsecured promissory note (the " Promissory Note ") in the principal amount of $140,000 to Bellevue Global Life Sciences Investors LLC (" BGLSI "), the sponsor of the Company.”
OSR Holdings, Inc. incurred loan of $50,000 with Bellevue Global Life Sciences Investors LLC at not interest bearing maturing December 31, 2024 or the date on which the Company consummates an initial business combination.
“On April 17, 2024, Bellevue Life Sciences Acquisition Corp. (the “ Company ”) issued an unsecured promissory note (the “ Promissory Note ”) in the principal amount of $50,000 to Bellevue Global Life Sciences Investors LLC (“ BGLSI ”), the sponsor of the Company.”
OSR Holdings, Inc. received a nasdaq extension granted notice regarding shareholders (rules 5550(a)(3)).
“April 17, 2024, the Company received a written notice from Nasdaq indicating that the staff of Nasdaq (the “ Staff ”) has determined, based on its review of the Company’s compliance plan, to grant the Company an extension of time to regain compliance with the Minimum Public Holders Requirement. The terms of the extension are as follows: on or before August 13, 2024, the Company must file with Nasdaq documentation from its transfer agent, or independent source, that demonstrates that its common stock has a minimum of 300 public holders. In the event the Company does not satisfy the terms, the S”
OSR Holdings, Inc. incurred loan of $1,200,000 with Bellevue Global Life Sciences Investors, LLC at not interest bearing maturing earlier of: (i) December 31, 2024 or (ii) the date on which the Company consummates an initial business combination.
“On April 8, 2024, Bellevue Life Sciences Acquisition Corp. (the “ Company ”) issued an unsecured promissory note (the “ Promissory Note ”) in the principal amount of $1,200,000 to Bellevue Global Life Sciences Investors, LLC (“ BGLSI ”), the sponsor of the Company. The Promissory Note is not interest bearing and is payable in full on the earlier of: (i) December 31, 2024 or (ii) the date on which the Company consummates an initial business combination (the “ Maturity Date ” ) .”
OSR Holdings, Inc. incurred loan of $60,000 with Josh Pan at not interest bearing maturing earlier of: (i) August 8, 2024 or (ii) the date on which the Company consummates an initial business combination.
“On March 8, 2024, Bellevue Life Sciences Acquisition Corp. (the “ Company ”) issued an unsecured promissory note (the “ Promissory Note ”) in the principal amount of $60,000 to Josh Pan”
OSR Holdings, Inc. received a nasdaq deficiency notice notice regarding other (rules 5550(a)(3)).
“February 15, 2024, Bellevue Life Sciences Acquisition Corp. (the “ Company ”) received a letter (the “ Notice ”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“ Nasdaq ”) notifying the Company that the Company no longer meets the minimum 300 public holders requirement for The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(3) (the “ Minimum Public Holders Requirement ”). In accordance with Nasdaq rules, the Company has 45 calendar days, or until April 1, 2024, to submit a plan to regain compliance with the Minimum Public Holders Requirement. If the”
OSR Holdings, Inc.: Stockholders approved a proposal to allow the Board to amend the Certificate of Incorporation to extend the deadline for consummating a business combination from February 14, 2024 to May 14, 2024 (effective 2024-02-09).
“At the special meeting of the Company’s stockholders held on November 9, 2023, the stockholders approved a proposal to give the Board the authority, in its discretion, to amend the Company’s Certificate of Incorporation (the “ Charter ”) to extend the date by which the Company must consummate a business combination from the February 14, 2024 to May 14, 2024. The Board authorized and approved a Certificate of Amendment to the Company’s Charter (the “ Charter Amendment ”) and the Charter Amendment was filed with the Delaware Secretary of State and has an effective date of February 9, 2024.”
OSR Holdings, Inc. incurred loan of $75,000 with Jun Chul Whang at not interest bearing maturing the earlier of: (i) August 9, 2024 or (ii) the date on which the Company consummates an initial business combination.
“On February 9, 2024, Bellevue Life Sciences Acquisition Corp. (the “ Company ”) issued an unsecured promissory note (the “ Promissory Note ”) in the principal amount of $75,000 to Jun Chul Whang, a member of the Company’s Board of Directors (the “ Board ”).”
OSR Holdings, Inc. incurred loan of $180,000 with Bellevue Capital Management LLC at not interest bearing maturing December 31, 2024 or the date on which BLAC consummates an initial business combination.
“On November 13, 2023, BLAC issued an unsecured promissory note (the “ Promissory Note ”) in the principal amount of $180,000 to Bellevue Capital Management LLC, a Washington limited liability company and the Manager of Bellevue Global Life Sciences Investors, LLC, the Sponsor of BLAC (“BCM”).”
OSR Holdings, Inc. entered into Business Combination Agreement with Bellevue Life Sciences Acquisition Corp. (effective 2023-11-16).
“On November 16, 2023, Bellevue Life Sciences Acquisition Corp., a Delaware corporation (“ BLAC ”), and OSR Holdings Co., Ltd., a corporation organized under the laws of the Republic of Korea (the “ Company ”), entered into a Business Combination Agreement (the “ Business Combination Agreement ”).”
OSR Holdings, Inc.: Amended certificate of incorporation to extend deadline for business combination from November 14, 2023 to February 14, 2024 (effective 2023-11-09).
“At the Special Meeting, the Company’s stockholders approved an amendment to the Company’s Amended and Restated Certificate of Incorporation (the “ Charter ”) to allow the Company to extend the date by which the Company must consummate a business combination from November 14, 2023 (the date that is 9 months from the closing date of the Company’s IPO) to February 14, 2024 (the “ First Extended Date ”).”
OSR Holdings, Inc. shareholders approved The Trust Amendment Proposal to amend the Trust Agreement to allow extensions of the liquidation date of the Trust Account. at the 2023-11-14 meeting.
“The Trust Amendment Proposal The stockholders approved the proposal to amend the Trust Agreement, allowing the Company to extend the date on which Continental must liquidate the Trust Account established by the Company in connection with the IPO if the Company has not completed its initial business combination, from November 14, 2023 to the First Extended Date by depositing into the Trust Account $180,000, plus, upon the Board exercising its discretion to further extend such date to the Second Extended Date, by depositing into the Trust Account by no later than each of February 14, 2024, March 14, 2024, and April 15, 2024, the lesser of (i) $60,000 or (ii) $0.026 per share for each public share, by the votes set forth in the table below: FOR AGAINST ABSTAIN BROKER NON-VOTES 6,985,910 250,998 — —”
OSR Holdings, Inc. shareholders approved The Second Extension Amendment Proposal to give the Board the authority to amend the Charter to extend the date by which the Company must consummate a business combination from the First Extended Date to the Second Extended Date..
“The Second Extension Amendment Proposal The stockholders approved a proposal to give the Board the authority in its discretion to amend the Company’s charter to extend the date by which the Company must consummate a business combination from the First Extended Date to the Second Extended Date, by the votes set forth in the table below: FOR AGAINST ABSTAIN BROKER NON-VOTES 6,935,730 301,178 — —”
OSR Holdings, Inc. shareholders approved The First Extension Amendment Proposal to amend the Charter to extend the date by which the Company must consummate a business combination from November 14, 2023 to the First Extended Date. at the 2023-11-14 meeting.
“The First Extension Amendment Proposal The stockholders approved the proposal to amend the Charter to extend the date by which the Company must consummate a business combination from November 14, 2023 to the First Extended Date, by the votes set forth in the table below: FOR AGAINST ABSTAIN BROKER NON-VOTES 6,985,910 250,998 — —”
OSR Holdings, Inc. amended First Amendment to Investment Management Trust Agreement with Continental Stock Transfer & Trust Company valued at Extends liquidation date from November 14, 2023 to February 14, 2024, with potential further extensi (effective 2023-11-10).
“On November 9, 2023, the Company held a special meeting of its stockholders (the “ Special Meeting ”). At the Special Meeting, the Company’s stockholders approved a first amendment to the Trust Agreement (the “ First Trust Amendment ”) that extends the date by which the Company must liquidate the trust account (the “ Trust Account ”) established in connection with the Company’s initial public offering (the “ IPO ”), from November 14, 2023 to February 14, 2024 (the “ First Extended Date ”) by depositing into the Trust Account $180,000 (the “ First Extension Payment ”) if the Company has not completed its initial business combination, and, upon the Board of the Directors of the Company (the “ Board ”) exercising its discretion to further extend the date by which the Company must liquidate the Trust Account if the Company has not completed its initial business combination, to May 14, 2024 (the “ Second Extended Date ”), by depositing into the Trust Account by no later than each of Februar”
OSR Holdings, Inc. incurred loan of $200,000 with Bellevue Global Life Sciences Investors LLC maturing earlier of December 31, 2024 or the date on which the Company consummates an initial business combination.
“On June 23, 2023, Bellevue Life Sciences Acquisition Corp., a Delaware corporation and blank check company (the “Company”), issued an unsecured promissory note (the “Note”) in the principal amount of $200,000 to Bellevue Global Life Sciences Investors LLC, the Company’s initial public offering sponsor (the “Sponsor”).”
OSR Holdings, Inc. received a nasdaq deficiency notice notice regarding audit committee (rules 5605(c)(2)(A), 5605(c)(4)(B)).
“June 27, 2023 that the Company is not currently in compliance with Nasdaq Listing Rule 5605(c)(2)(A) (the “Listing Rule”), but that it intends to regain compliance within the cure period provided by section (c)(4)(B) of the Listing Rule. The Listing Rule requires the Audit Committee (the “Audit Committee”) of the Company’s Board of Directors (the “Board”) be composed of at least three members, each of whom must meet independence requirements under the Nasdaq Listing Rules and the Securities Exchange Act of 1934, as amended. Upon the effective date of Mr. Euh’s resignation from the Company’s”
Mr. Jin Whan Park was appointed as Director at OSR Holdings, Inc..
“On February 14, 2023, in connection with Bellevue Life Sciences Acquisition Corp.’s (the “Company”) initial public offering (“IPO”), Dr. Steven G. Reed, Dr. In Chul Chung, Dr. Rad Roberts, Mr. Hosun Euh, and Mr. Jin Whan Park were each appointed to the board of directors of the Company (the “Board”) as independent directors, with Dr. Reed serving as Chairman of the Board.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.